CancerRadarCancerRadar
RadiopharmaceuticalFDA-approvedSecond-line

Lutetium Lu 177 vipivotide tetraxetan

Generic name: lutetium lutetium-177 vipivotide tetraxetan

How it works

Delivers targeted radiation to prostate cancer cells, causing DNA damage and cell death.

Cancer types

Prostate Cancer

Efficacy

Studies show that approximately 30% of patients with metastatic castration-resistant prostate cancer achieved a PSA response, with a median overall survival of around 14 months.

Side effects

Severe

This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.

This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.